Orphenadrinhydrochlorid

greater than or equal to 100 mg/mL at 66 °F (NTP, 1992)

>45.9 [ug/mL] (The mean of the results at pH 7.4)

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Danger

H301 (97.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 3 notifications to the ECHA C&L Inventory.

SYMPTOMS: Symptoms of exposure to this compound include dryness of mouth, loss of accommodation, dilated pupils, photophobia, increased intraocular pressures, difficulty in swallowing, thirst, flushing and dryness of the skin, transient bradycardia followed by tachycardia with palpitations and arrhythmias, urinary retention, reduction in the tone and motility of the gastrointestinal tract leading to constipation, vomiting, giddiness, staggering, retrosternal pain due to increased gastric reflux, rapid or stertorous respiration, hyperpyrexia restlessness, confusion, excitement, hallucinations, delirium and rash on the face and upper trunk. Severe exposure may cause central nervous system depression with hypertension or with circulatory failure and respiratory depression. There have been cases of dizziness, involuntary jerky movements of the limbs, nervous movements and burning sensation in the throat. Other symptoms of exposure include blurred vision, cyanosis, mydriasis with absent light reflex, coma, clonic convulsions, respiratory arrest and alarming disturbances in cardiac mechanisms. In young children, exposure can cause severe intoxication and death. Glaucoma and widely dilated unreactive pupils have been reported. Symptoms of exposure to this type of compound include lethargy, drowsiness, fatigue, hypnosis, vertigo, ataxia, tinnitus, central nervous system hyperexcitability, sedation, tremors, anxiety, insomnia, toxic psychoses, gastrointestinal disturbances, anorexia, nausea, abdominal distress, diarrhea and pulmonary edema. Other symptoms of exposure to this type of compound include headache, nervousness, disorientation, stupor, hyperreflexia, nystagmus and hyperthermia.

N - Nervous system

QN - Nervous system

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)

Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2B6.